<DOC>
	<DOCNO>NCT01889433</DOCNO>
	<brief_summary>The purpose study demonstrate noninferiority Algeron combination ribavirin compare Pegasys combination ribavirin treatment chronic hepatitis C .</brief_summary>
	<brief_title>An Open-label Comparative Efficacy Safety Study Algeron ( Cepeginterferon Alfa-2b ) Treatment-naive Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>The course treatment group shall 12 week , efficacy analysis , i.e . rate rapid ( 4th week ) early ( 12th week ) virologic response base PCR data . For patient treatment failure 12th week antiviral therapy shall discontinue . All patient require anti-viral treatment receive combination treatment Algeron / Pegasys ribavirin another 12 36 week ( depend HCV genotype ) . Sustained virologic response assess 24 week last dose study treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Signed informed consent participate study . 2 . Chronic HCV infection ( genotypes 1а , 1b , 2 , 3 , 4 ) detectable HCV RNA &gt; 6 month screen visit abnormal ALT level &gt; 6 month screen visit . 3 . Male female patient , 18 70 year age , inclusive . 4 . Body mass index 18 30 kg/m2 . 5 . Preserved protein synthetic liver function ( INR &lt; 1.7 , albumin &gt; 35 g/l ) . 6 . No sign hepatic encephalopathy abdominal fluid retention accord clinical ultrasound examination . 7 . Fertile patient partner agree use barrier contraception throughout study treatment 7 month . 8 . Patient must documentation fibroscan within 1 year screen visit agree fibroscan within screen period . 1 . Intolerance IFN alfa , ribavirin component preparation confirm past medical history . 2 . Infection hepatitis B , A , E virus HIV ( coinfection ) . 3 . Any documented significant liver disease ( drug alcoholrelated cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , biliary cirrohosis , etc. ) . 4 . Past history HCV treatment IFN alfa pegylated IFN alfa . 5 . Administration injectable noninjectable interferon and/or interferon inducer indication ( HCV ) one month enrollment study . 6 . Cholestatic hepatitis ( level conjugate bilirubin , alkaline phosphatase , GGTP exceed upper normal level 5 time ) . 7 . Decompensated liver cirrhosis confirm laboratory finding ( class B , С accord ChildPugh ) ultrasound examination . 8 . Any documented autoimmune disease ( e.g. , Crohn 's disease , ulcerative colitis , systemic lupus erythematosus , idiopathic thrombocytopenic purpura , scleroderma , autoimmune haemolytic anemia , severe psoriasis ) . 9 . Hemoglobin low low normal level ; neutrophil &lt; 1.5 х109/L ; platelet &lt; 90 х109/L ; creatinin level exceed upper normal level 1.5 time , ALT level exceed upper normal level 10 time . 10 . Documented hemoglobinopathy ( e.g. , thalassemia major , sicklecell anemia ) . 11 . Severe depression , schizophrenia , mental disorder , investigator 's point view contraindication antiviral treatment . 12 . Epilepsy and/or disorder function central nervous system . 13 . Abnormal thyroid function ( TTH level beyond normal value ) . 14 . Diagnosed suspect hepatocellular carcinoma evidence screen alfafetoprotein ( AFP ) ≥ upper normal level . 15 . Antinuclear antibody ( ANA ) titer ≥1:640 screen and/or evidence autoimmune hepatitis liver biopsy . 16 . Malignant neoplasm . 17 . Pregnancy , lactation period . 18 . Severe comorbidities ( example , severe hypertension , severe coronary heart disease , decompensated diabetes mellitus ) represent contraindication antiviral treatment . 19 . Documented rare hereditary disease , intolerance lactose , sucrose , fructose , lactase deficiency glucosegalactose malabsorption . 20 . Known drug alcohol abuse sign drug/alcohol abuse present , investigator 's point view contraindication antiviral treatment restrict adherence treatment regimen . 21 . Simultaneous participation clinical study less 30 day enrollment study previous participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Cepeginterferon alfa</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Treatment</keyword>
</DOC>